Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955913 · ClinicalTrials.gov registry record
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 3,679
- Enrollment target
NCT03955913 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 3,679 participants.
The verdict
NCT03955913 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 3,679 participants
- Enrollment target
Study Summary
The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
Interventions
- OTHER Archival Tumor Tissue Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,679 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2022-09-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955913
The ClinicalTrials.gov registry entry for NCT03955913 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,679 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Archival Tumor Tissue Sample is the first listed.
NCT03955913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03955913 about?
NCT03955913 is a clinical study titled "A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations". The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
What is the current status of trial NCT03955913?
This trial is currently completed. The enrollment target is 3,679 participants. The study started on 2019-08-01. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT03955913?
The interventions under investigation include: Archival Tumor Tissue Sample (OTHER).
Who is sponsoring clinical trial NCT03955913?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.